NCT05923814尚未招募2 期
The Administration of Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Patients Older Than 50y Underwent HID-HSCT
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- the incidence of aGVHD
研究概览
简要总结
Age is no longer a barrier to successful allogeneic hematopoietic cell transplantation. However, the incidence of aGVHD is still high among the elderly, especially for patients receiving HID-HSCT. We designed this clinical trial to use humanized CD25 antibody for aGVHD prophylaxis among in elderly patients aged 50 and older. The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) hematological malignances patients underwent HLA-haploidentical donor HSCT. (2) Age elder than or equal to 50 years; (3) Informed consent may be signed by themselves. (4) HIV negative, HBV, HCV negative; (5) Informed consent must be signed before the start of the study procedures, and informed consent must be signed by the patient himself or his immediate family. Considering the patient 's condition, if the patient' s signature is unfavorable for disease treatment, the informed consent form should be signed by the legal guardian or the patient 's immediate family member.
排除标准
- •(1) received a previous allogeneic HSCT; (2) Uncontrolled infection at enrollment; requires mechanical ventilation or is hemodynamically unstable at the time of enrollment; (3) has severe hepatic insufficiency (defined as Child-Pugh Class C; has serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 xthe upper limit of normal (ULN) or serum total bilirubin > 2.5 x ULN.
- •(4) has end-stage renal impairment with a creatinine clearance less than 10 mL/min.
- •(5) has both moderate hepatic insufficiency AND moderate renal insufficiency; (6) has documented positive results for human immunodeficiency virus antibody (HIVAb), hepatitis C virus antibody (HCV-Ab) with detectable HCV RNA, or hepatitis B surface antigen (HBsAg) within 90 days prior to enrollments; (7) has active solid tumor malignancies with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (e.g., lymphomas).
- •(8) Suffering from mental disorders or other conditions and unable to cooperate with the requirements of study treatment and monitoring; (9) unable or unwilling to sign the consent form; (10) patients with other special conditions assessed as unqualified by the investigator
研究组 & 干预措施
treatment arm
Experimental
干预措施: CD25 prophylaxis (Drug)
结局指标
主要结局
the incidence of aGVHD
时间窗: 24 weeks after HSCT
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid MalignanciesHaemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is WarrantedNCT01566656Nantes University Hospital15
尚未招募
不适用
Allo-HSCT vs ASCT in Adult T-LBLT Lymphoblastic LymphomaNCT06741813Peking University People's Hospital230
进行中（未招募）
不适用
Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory ?Triple Negative? Breast Cancer - NDPatients with Refractory ?Triple Negative? Breast CancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-006262-28-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
不适用
Trends in allogeneic hematopoietic cell transplantation for adult ALL over the past three decadesAcute lymphoblastic leukemiaJPRN-UMIN000047159agoya University Hospital8,467
进行中（未招募）
不适用
Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies - NDPreparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic MalignanciesMedDRA version: 6.1Level: PTClassification code 10028228EUCTR2007-005563-10-ITFONDAZIONE NEOPLASIE SANGUE ONLUS